A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Status:
Recruiting
Trial end date:
2025-05-04
Target enrollment:
Participant gender:
Summary
Participants of this study will have a diagnosis of a solid tumor cancer that has come back
to its original location or spread beyond its original location (advanced), came back
(relapsed) or worsened (refractory) after standard treatments, or no standard treatments are
available for the participants' cancer. The purpose of this study if to find the highest dose
of MQ710 that causes few or mild side effects in participants with a solid tumor cancer
diagnosis.